Results 91 to 100 of about 6,775 (167)

Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Oncology and Therapy
Introduction Compared with chemoimmunotherapy, both zanubrutinib monotherapy and venetoclax plus obinutuzumab prolong progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL). Matching-adjusted indirect comparison (MAIC) can be
Talha Munir, Nicolás Martinez-Calle, Sheng Xu, Keri Yang, Xiaoyun Ge, Ayad K. Ali, Leyla Mohseninejad, Balázs Dobi, Pal Rakonczai, Han Ma, Rhys Williams, Wassim Aldairy, Nicole Lamanna   +12 more
doaj   +1 more source

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. [PDF]

Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia. We present results from ELEVATE-TN after a median follow-up of 74.5 months. Overall, 535 patients were randomized (acalabrutinib-obinutuzumab,
Munir, Talha, Kamdar, Manali, Flinn, Ian W., Banerji, Versha, Byrd, John C, Suterwala, Batul T., Hughes, Marie, Munugalavadla, Veerendra, Wun, Chuan-Chuan, Herishanu, Yair, Woyach, Jennifer A., Jurczak, Wojciech, Patel, Krish, Fogliatto, Laura Maria, Woyach, Jennifer A, Ferrant, Emmanuelle, Janssens, Ann, Sharman, Jeff P., Flinn, Ian W, Walker, Patricia, Ferrajoli, Alessandra, Skarbnik, Alan, Follows, George, Miranda, Paulo, Wierda, William G, Sharman, Jeff P, Walewska, Renata, Suterwala, Batul T, Byrd, John C., Wierda, William G., Egyed, Miklos, Ghia, Paolo, Wachira, Catherine Wangui   +32 more
core   +1 more source

Successful management of belimumab after obinutuzumab in a patient with systemic lupus erythematosus: a case report with an 18-month follow-up

Frontiers in Immunology
IntroductionSystemic lupus erythematosus (SLE) is a complex autoimmune disease, and despite the availability of multiple treatments, striking a balance between long-term efficacy and side effects remains a major clinical challenge.
Xiuxiu Pu, Xiuxiu Pu, Qiao Ye, Lin Zhu, Lin Zhu, Tingting Yan   +5 more
doaj   +1 more source

Reduced-dose obinutuzumab induces remission in refractory ANCA-associated vasculitis: a report of 16 cases

Frontiers in Immunology
ObjectiveRituximab remains the standard-of-care anti-CD20 therapy for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Obinutuzumab, a next-generation, glycoengineered anti-CD20 monoclonal antibody with enhanced B-cell-depleting ...
Wenyi Wu, Juan Wang, Sheng Chen
doaj   +1 more source

Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients

Frontiers in Immunology
BackgroundThere has been an annual rise in the incidence of primary membranous nephropathy (PMN), a common pathological type of nephrotic syndrome (NS). Obinutuzumab is a humanised, glycosylated, type II anti-CD20 monoclonal antibody.
Qi Gao, Guoxiang Yao, Yujiao Sun, Xiaoyun Li, Zhuo Li, Bing Chen   +5 more
doaj   +1 more source

Safety assessment of obinutuzumab: Real-world adverse event analysis based on the FAERS and JADER databases from 2013 to 2025.

PLoS ONE
BackgroundObinutuzumab is the first glycosylated type II anti-CD20 monoclonal antibody for the treatment of lymphocytic leukemia and follicular lymphoma.
Xiangpeng Li, Haonan Liang, Ping Leng, Zhanqi Cao   +3 more
doaj   +1 more source

Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors. [PDF]

The immunocytokine cergutuzumab amunaleukin (CEA-IL2v) showed manageable safety and favorable pharmacodynamics in phase I/Ib trials in patients with advanced/metastatic carcinoembryonic antigen-positive (CEA+) solid tumors, but this was accompanied by a ...
Melero, I., Steeghs, N., Alonso-Gordoa, T., Dejardin, D., Charo, J., Pisa, P., Leutgeb, B., Rossmann, E., Klein, C., Umana, P., Dal Porto, J., Angevin, E., Watson, C., Rohrberg, K., Mellado, B., Evers, S., Perez-Gracia, J.L., Del Nagro, C., Tabernero, J., Peters, S., Nicolini, V., Saro, J., Adessi, C., Boetsch, C., Teichgräber, V.   +24 more
core   +1 more source

Clinical application of obinutuzumab for treating chronic lymphocytic leukemia

Drug Design, Development and Therapy, 2019
Chunyan Luan, Baoan ChenDepartment of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu Province 210009, People’s Republic of ChinaCorrespondence: Baoan ChenDepartment of Hematology and Oncology ...
Luan C, Chen B
doaj  

Durability Benchmarking of Contemporary Second-Line and Later Therapies for Relapsed or Refractory Follicular Lymphoma Using Reconstructed Individual Patient Data From Published Kaplan-Meier Curves. [PDF]

Cureus
Burke OJ, Peruzzo N, Tul Ain Khan N, Kancharla P.   +3 more
europepmc   +1 more source

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study. [PDF]

Cancer Med
Liao PW, Ko BS, Su YC, Chao WT, Teng CJ.
europepmc   +1 more source